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Biotechnology Overview: 1987 
JEFFREY L. FOX 
jeffrey L. Fox is a freelance science writer in Washington D. C., currently affiliated with Rio/Technology and ASM News. 
"'Biotechnology' is a terrible term," says David Kingsbury of 
the National Science Foundation, who has been chairing the 
federal-wide effort to coordinate biotechnology regulations 
and guidelines (1). Although definitions of biotechnology 
have changed often during recent years, the word's meaning 
has seldom proved a serious stumbling block However, in 
1986, federal officials renewed the debate over how best to 
define the term because of a troublesome dilemma they find 
themselves facing. Indeed, even their reluctance to close this 
long-lived debate suggests a useful purpose is being served by 
keeping the definition of biotechnology from becoming too 
precise. 
The dilemma over biotechnology arises because of the dual 
missions of research and regulation for which so many federal 
agencies are responsible. As interest in biotechnology grew 
rapidly during the past 5 to 10 years, members of Congress 
have pressed agency officials to show they were giving proper 
support to this emerging enterprise. Although its growth in 
the private sector has been fast and enormous, no one ques-
tions the impetus stemmed from federally sponsored 
research-originally, largely from basic biomedical research 
underwritten by the National Institutes of Health (NIH). Other 
agencies have been urged to join in supporting biotechnology 
and, wherever possible, to induce researchers whom they 
fund to modernize their own efforts by adopting its powerful 
tools. 
Following that path has not proved a straightforward 
assignment, however. Because many of the same federal 
agencies also share a responsibility for regulating biotechnol-
ogy research and its products, agency officials often find 
themselves faced with two very different agendas on the same 
topic. In particular, techniques used widely within biotech-
nology, especially manipulations involving recombinant DNA 
techniques, have come under close regulatory scrutiny. 
Although this attention has been deemed critical for ensur-
ing both public confidence and safety, it tends to slow pro-
gress. Some federal officials now are increasingly worried that 
the biotechnology regulatory net may be opening too widely. 
In the rush to redirect and reclassifY agency research efforts, 
making them better attuned to biotechnology's promise, the 
scope of regulation may also have been inadvertently broad-
ened too much. 
Federal Panels Refining Biotechnology 
Regulatory Roles 
During the January 1987 meeting of the interagency Bio-
technology Science Coordinating Committee (BSCC), efforts 
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were made to clarifY lingering confusion about the commit-
tee's role in federal biotechnology policy-making. The upshot 
of the latest discussions is that BSCC is strictly a coordinating 
body-overseeing a scientific debate, albeit with many regu-
latory implications-but not a regulatory body. Although this 
role was set at BSCC's inception, the flurry of documents, 
discussions, and lawsuits surrounding proposed federal bio-
technology policies in 1986 tended to obscure this circum-
scribed but not inconsequential charter. 
Assembling information and arriving at a consensus are not 
proving easy tasks for federal officials dealing with biotech-
nology. At best, the defining of certain key terms, such as 
"pathogen" and the "deliberate release of genetically engi-
neered organisms," is turning out to be a reiterative process. 
The proposals that were published in the Federal Register 
prompted an outpouring of critical and contradictory com-
ments ( 4). Thus, not only are the proposals now not consi-
dered "enforceable" in a legal sense, they also are proving to 
be just another round in a continuing cycle among scientists 
from different disciplines who are seeking a purely scientific 
consensus. 
In addition to the BSCC's efforts to massage that collective 
information, other federal agencies are going through a sim-
ilar process. It could take most of 1987 before the details of 
this exercise are worked out. 
For example, to the Recombinant DNA Advisory Committee 
(RAC) of the NIH, the issue of how to define the deliberate, or 
"planned," release of genetically engineered organisms into 
the environment has become a key but largely symbolic stick-
ing point. At its February 1987 meeting, the committee urged a 
further easing on current restrictions, an abstract maneuver 
that can succeed only if other federal agencies evaluating 
actual plans for such experiments heed NIH's intellectual 
lead. Moreover, despite limiting its role reviewing most 
recombinant DNA proposals that go to federal regulatory 
agencies, the committee reaffirmed its intent to evaluate plans 
for human gene therapy experiments, which also fall under 
jurisdiction of the Food and Drug Administration (FDA). 
Meanwhile at the Environmental Protection Agency (EPA), 
science advisory panels consisting of outside experts have 
been convened to help agency staff members develop a better 
definition of deliberate release. The improved definition is 
expected to serve as a guide for when projects involving a 
"significant new use" of a microbe in the environment, a 
release for research and development of a commercial pro-
duct, or organisms falling under jurisdiction of the Toxic 
Substances Control Act should undergo review by the agency. 
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Fine tuning a definition to meet this goal is not proving a 
straightforward chore. 
Courts Playing Key Role in Shaping Regulations 
The U. S. District Court late in 1986 dismissed two lawsuits 
brought by activist Jeremy Rifkin protesting how the federal 
government proposes to regulate biotechnology (2, 3). In 
both cases, Judge Gerhard A. Gesell concluded the issues 
were "not ripe" for litigation and that Rifkin and his Founda-
tion on Economic Trends lack standing to oversee what are 
properly federal policy-making prerogatives (2). The judge's 
decisions could represent a serious setback to Rifkin's hereto-
fore most effective tactic-taking legal action to slow the 
progress of genetic engineering. In a separate action also 
brought by Rifkin, the courts have ordered the Department of 
Defense (DoD) to prepare an environmental impact state-
ment for its entire biotechnology-based biological warfare 
defense program. 
In one of his lawsuits, Rifkin (3) was seeking to prevent the 
President's Office of Science and Technology Policy ( OSTP) 
from implementing its "Coordinated Framework for Regula-
tion of Biotechnology," proposed in the Federal Register in 
June 1986 (2 , 4, 5). In the second suit, Rifkin was objecting to 
EPA's procedures for evaluating experiments involving delib-
erate release of genetically engineered organisms (3 ). In the 
third suit, Rifkin and the other plaintiffs alleged that the DoD 
was careless in conducting research on certain pathogens and 
thus the whole biological warfare program needed a thorough 
review for safety as well as improvements in security proce-
dures (3) . 
Rifkin's action against EPA dates back to May 1986 when he 
petitioned the agency to change its procedures for evaluating 
and registering genetically engineered "pesticides" (3 ).Judge 
Gesell cited Supreme Court decisions indicating the court 
cannot settle grievances involving alleged injuries that are 
merely "abstract, conjectural, or hypothetical." Thus, he 
turned down Rifkin 's lawsuit, calling its grievances "wholly 
abstract. " Although Judge Gesell said that the issues brought 
up in Rifkin's lawsuit are not ripe for judicial review, he left 
open the possibility of conducting such review later, but "in a 
far more concrete factual setting" (2) . 
In the second lawsuit, Rifkin wanted the court to declare 
OSTP's proposed Coordinated Framework for Regulation of 
Biotechnology illegal. He argued that the inexactness of the 
definitions that are laid out in the framework could lead to 
incomplete and possibly dangerous regulation of genetically 
engineered products. He also said the document needed to 
be accompanied by an environmental impact statement (3). 
Judge Gesell again rejected Rifkin's claims, saying in effect 
that Rifkin was accusing the framework of failing at something 
it is not intended to do. "While the document is not a model of 
clarity ... [its contents] are ... to guide policy-making, not to reg-
ulate," the judge says in his decision. Moreover, the frame-
work is "merely a first effort to aid in formulation of agency 
policy ... [and] the definitions do not authorize agency action 
that could not otherwise take place." Thus, the judge con-
cludes that Rifkin's legal action was premature, based on 
"abstract speculation about what the agencies involved may 
do in the future" (2). 
In yet another lawsuit, DoD was told in February 1987 by a 
U.S. District Court judge to prepare a comprehensive envir-
onmental impact statement for its biological defense research 
program, much of which involves applications ofbiotechnol-
ogy warfare. Judging just who won this round ultimately 
reflects on an assessment of Rifkin and the military's inten-
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tions. Rifkin asserts there are hints of sinister activities within 
DoD's overall program. DoD scientists retort that their 
research aims are legitimate and that valuable efforts to com-
bat dangerous, sometimes woefully neglected diseases may 
be hampered because ofRifkin 's meddling. They also suggest 
that Rifkin's allegations are by now a familiar means for gain-
ing publicity. Rifkin says it is his duty to slow DoD's progress, 
which he sees as leading inevitably towards weapons devel-
opment, by being a "pain" (6). 
The DoD programs include developing pathogen detection 
systems, vaccines, and biological safety suits to protect against 
potential biological warfare agents. Top Defense Department 
officials have maintained that the United States follows the 
Geneva Conventions forbidding development and produc-
tion of biological weapons and thus all work being done is 
strictly for defensive purposes. DoD's research is conducted in 
many facilities across the country, with a sizable fraction of it 
being done under contract in university settings. ( 6). 
Although some DoD scientists question the need for a 
comprehensive review because they believe their laboratory 
practices are safe and environmentally sound, they view it as 
potentially a "worthwhile exercise" for proving their case in 
"the eyes of the public." However, they also say the suit has 
been an "embarrassment" because of its "implications of 
wrong doings," which they vigorously deny. According to 
several observers, Rifkin 's actions ironically could lead DoD 
into a more secretive posture. If DoD eventually insists on 
classifying much of the material in the environmental impact 
statement, notes another observer, later efforts to use that 
material for delaying particular components of biological war-
fare programs are that much more likely to prove fruitless (6). 
Public Interest Groups Revising Their 
Biotechnology Agenda 
Besides Rifkin, other members of the public interest com-
munity, including Barry Commoner and Ralph Nader, con-
vened in November 1986 at a meeting, "Creating a Public 
Agenda for Biotechnology: Health, Food, and the Environ-
ment," sponsored by the Boston-based Committee for 
Responsible Genetics ( CRG). Also attending the meeting 
were activists from West Germany, including members of the 
Green Party, who provided a flavor for the militant opposition 
to biotechnology that is developing in parts of Western 
Europe. 
Commoner and Nader, although comparative newcomers 
to the biotechnology scene, seem eager to match Rifkin in 
their accusations against the new industry. Indeed, they 
offered strong and dire warnings of biotechnology's future 
misdeeds, based mainly on their appraisals of other tech· 
nology-based industries. 
Other elements of the public interest community showed 
themselves eager to join Rifkin, Nader, and Commoner in 
their watchdog roles. Just where they want to go, or why, is not 
so easy to say, however. Is biotechnology to be blocked 
'altogether, or do the activists see themselves correcting the 
young industry's "exploitative" tendencies and putting it onto 
a track that better meets with their approval? No clear consen-
sus has emerged. 
Some efforts within biotechnology seem to have members 
of the public interest community especially perplexed. For 
instance, factions from among groups represented at the CRG 
meeting declared themselves interested in developing partic-
ular biotechnology-based products, especially vaccines, to 
benefit countries of the developing world. Vaccines are quite 
appealing to many members of the public interest commun-
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ity, who recognize their value as a preventive, cost-effective 
means for tackling difficult disease problems in both indus-
trialized and developing countries. They claim, however, that 
current profit-minded companies are failing to supply that 
need, and will continue to fail unless invested with social 
consciences. 
Important Developments but also Frustrations 
for Farm Sector 
In response, some industrial biotechnologists are calling 
upon leaders from the academic community to come forward 
and "demystify" genetic engineering. "We should not let a 
handful of idealogues set public policy," says Howard 
Schneiderman, senior vice president for research and devel-
opment at Monsanto Corp. in St. Louis. "The new technology 
will hasten the change of U.S. agriculture-whether or not it is 
adopted by U.S. farmers," he adds. "[They must] either 
become innovative farmers or compete with one." (7). 
Biotechnology's most ardent critic, Jeremy Rifkin, has 
argued that some of the first agricultural products of genetic 
engineering should be rejected, among other reasons, on 
economic grounds. For example, administering growth hor-
mone (also called somatotropin) to dairy cows to increase 
milk production when there already is a milk glut would drive 
many small dairy farmers out of business, he argues. Such 
reasoning is the basis of one of his many legal actions to block 
biotechnology. 
Proponents of this new hormone-based technology have 
developed several counterarguments. For example, according 
to economist Robert Kalter of Cornell University in Ithaca, 
New York, genetically engineered growth hormone could 
prove relatively cheap for small dairy farmers because its use 
entails no capital cost, but only the added cost of buying and 
administering the hormone. Moreover, its use would reduce 
feed, land, and numbers of cows needed per unit of 
production-all of which may benefit small farm operations. 
Because the diets of hormone-treated animals would need 
substantial adjusting, the biggest changes might be expected 
in land use, with demand increasing for land to grow high-
protein soybeans but decreasing for land for other feed, such 
as corn (7). 
Still other arguments are being advanced on behalf of 
growth hormone's use in agriculture. Not only does it boost 
milk production and feed efficiency in dairy cattle, it also 
improves productivity in hogs and cattle being raised for meat. 
Perhaps more significantly, the hormone dramatically de-
creases the fat content of meat, and it leaves no residues, 
according to Thomas Wagner of Ohio University in Athens. 
Thus, it could be a safer alternative to both antibiotics used in 
subtherapeutic doses and steroid hormones for boosting pro-
duction in livestock, he says. Moreover, lowering fat content of 
meat could prove more healthful to consumers, who have 
been urged by health authorities to eat less animal fat to help 
prevent heart disease and cancer. 
If the foodstuffs of the genetic engineering era are being 
portrayed as beneficial to consumers, other biotechnology 
wares are being called "friendly to the environment." 
Moreover, sometimes industrial successes may come by fol-
lowing "mid-level" instead of high technology, according to 
David Reed of Molecular Genetics Inc. in Minnetonka, Minn. 
(7). Although Reed did not say as much, another advantage of 
such a strategy, besides the often faster development of useful 
technologies, is a lower regulatory profile to the industry's 
critics. Rifkin, for instance, seldom has strayed from matters 
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that directly involve recombinant DNA techniques. Other 
novel biotechnologies usually are spared his obstructionism. 
Confidence in Other Industry Sectors Growing 
Although experts are frustrated by current regulatory uncer-
tainties now retarding biotechnology's application, particu-
larly in the agriculture and food industries, they also evince 
confidence in their own growing scientific and technical 
know-how. They claim that biotechnology not only will 
benefit farmers and food processors but also consumers, 
whose food will become cheaper and more nutritious. And 
growth in the pharmaceutical industry already is having an 
impressive impact. 
The biotechnology industry has reached "young adult-
hood," according to financial analyst Linda I. Miller, who 
follows its commercial developments for Paine Webber Inc. in 
New York City. According to her financial overview of the 
industry, it is youthful but apparently thriving ( 8 ). Moreover, 
the pharmaceutical industry, in offering an overview of its 
1986 performance, is emphasizing how much money is being 
poured into research by the industry. Representatives from the 
industry point with pride to four biotechnology-based phar-
maceutical products approved by the Food and Drug Adminis-
tration (FDA) last year and say they expect this segment of the 
industry also to continue growing. Incremental changes for 
biotechnology research support also are embedded in the 
Administration's budget for fiscal year (FY) 1988. (Also, see 
Table 1, which indicates comprehensive federal budget fig-
ures for FY 1985.) 
Table 1. GAO report summarizes biotechnology research support 
among selected federal agencies in Fy 85* 
Agency Total R&D Biotechnology R&D 
$ millions/number $ millions/number 
projects projec s 
USDA 
ARS 470/2300 25/NA 
CSRS 284/12,250 48/750 
EPA 320/NA 1/19 
FDA 82/NA 3/17 
NIH 4,824/30,000 1849/NA 
NSF 1 ,346/14,157 82/1,621 to 1,773 
*Source: "Biotechnology: Analysis of Federally Funded Research," U.S. 
General Accounting Office Report RCED-86-187. 
Abbreviations: R&D= research and development; FY =fiscal year; USDA 
= U_S. Department of Agriculture; ARS =Agricultural Research Service; 
CSRS = Cooperative State Research Service; EPA = Environmental 
Protection Agency; FDA = Food and Drug Administration; NIH = 
National Institutes of Health; NSF= National Science Foundation; NA = 
not available 
The biotechnology industry has grown to an impressive 
size in the past few years, according to Miller. Wall Street now 
accords the 50 or 60 publicly held companies an overall value 
of $9 to $10 billion, based on the selling price of the available 
aggregate stocks. Last year was a healthy year in terms of how 
much new money was put into the industry by investors, she 
notes. Marketplace funding accounted for about $800 million 
worth of investment in 1986, and private placements pushed 
last year's total private sector investment over $1 billion (8). 
All this money is pouring into companies whose promises 
for products and profits are largely still to be realized. None-
theless, more and more products are making their way into 
the marketplace, with estimates for total sales in 1986 of 
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almost $500 million, which could double this year, Miller says. 
The industry still is reporting overall losses but may break 
even in 1987, particularly if several promising drugs are 
approved for use in humans (8). 
Most of the biotechnology-based products now being sold 
are medical diagnostic devices, with only a handful of human 
therapeutic products yet approved. Thus, although about two-
thirds of the private-sector biotechnology investment sup-
ports research and development of products for human ther-
apy, they still represent a much smaller fraction of sales-re-
flecting the relatively more complicated approval process for 
them. Diagnostic products, by contrast, receive only about 
10% of the overall investment but currently account for about 
55% of all sales. 
So far, at least, the development costs for biotechnology-
based products have been lower than those typical for new 
chemical drugs, Miller continues. The new industry has had 
relative good fortune with regulators, she says, particularly in 
receiving expeditious review by the FDA. Patent fights, state 
and local regulations, the effect of federal efforts to reduce 
hospital costs (hence, possibly also to lower the costs of drugs 
and diagnostic products) , and the return of inflation are 
among the issues that could prove to cause difficulties in the 
future (8). 
From the group of pharmaceuticals approved in 1986, four 
products were derived from biotechnology: a monoclonal 
antibody for preventing immune rejection of kidney trans-
plants ( Orthoclone, developed by Ortho Pharmaceutical 
Corp.), two versions of alpha interferon for treating hairy cell 
leukemia (Intron A. developed by Schering-Plough Corp.) 
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and Roferon A, developed by Hoffmann-La Roche Inc., and a 
recombinant DNA-based vaccine for preventing hepatitis B 
(Recombivax HB, developed by Merck Sharp & Dohme). 
According to Pharmaceutical Manufacturers Association 
(PMA) president Gerald Mossinghoff and his colleague Will-
iam Szkrybalo, 1, 232 U.S. biotechnology patents were issued 
in 1986, an increase of 14% over 1985. Although about half 
those patents were for pharmaceutical and healthcare pro-
ducts, nearly two-thirds of the patents in this subgroup were 
awarded to individuals not at U.S. firms (9). 
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